Information for the pancreatic cancer patient and their loved ones

The Pancreatic Duct

 

 

More than 30,000 people in the United States and 60,000 Europeans will learn that they have pancreatic cancer this year.

The Pancreatic Duct is intended to offer a solid introduction to pancreatic cancer. It is intended to provide credible information about pancreatic cancer to enable the patient and their loved ones to learn about the disease. To help them to understand and better accept what is happening to them. And to help them participate effectively as an active part of their health care team.

Information about the founder of this site and his experiences with pancreatic cancer are located in the Founder section.

Alternative Medicine Neuroendocrine Tumors
Causes/Risk Factors of Pancreatic Cancer Symptoms of Pancreas Cancer
Pancreatic Cancer For Health Professionals Tests/Diagnosis for Pancreatic Cancer
Pancreatic Cancer For Patients   Treatment of Pancreatic Cancer
Pancreatic Cancer from Medical Authorities  

 

Recent Select Abstracts in pancreatic cancer
For access to all abstracts back to 2003, please click here

Lapatinib/Gemcitabine and Lapatinib/Gemcitabine/Oxaliplatin: A Phase I Study for Advanced Pancreaticobiliary Cancer.
Safran H, Miner T, Resnick M, Dipetrillo T, McNulty B, Evans D, Joseph P, Plette A, Millis R, Sears D, Gutman N, Kennedy T.
Am J Clin Oncol. 2008 Apr;31(2):140-4. The Miriam Hospital, Brown University Oncology Group, Providence, Rhode Island.
[Link to Abstract]

Oral Capecitabine in Gemcitabine-Pretreated Patients with Advanced Pancreatic Cancer.
Boeck S, Wilkowski R, Bruns CJ, Issels RD, Schulz C, Moosmann N, Laessig D, Haas M, Golf A, Heinemann V.
Oncology. 2007;73(3-4):221-7.[Epub 2008 Apr 17]. Klinikum Grosshadern, Ludwig Maximilians University of Munich, Germany.
[Link to Abstract]


PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) Regimen as Second-Line Therapy in Patients with Progressive or Recurrent Pancreatic Cancer after Gemcitabine-Containing Chemotherapy.
Reni M, Cereda S, Mazza E, Passoni P, Nicoletti R, Balzano G, Zerbi A, Arcidiacono PG, Staudacher C, Di Carlo V.
Am J Clin Oncol. 2008 Apr;31(2):145-50. S. Raffaele Scientific Institute, Milan, Italy.
[Link to Abstract]


A Phase II Study Evaluating Bevacizumab in Combination with Fixed-Dose Rate Gemcitabine and Low-Dose Cisplatin for Metastatic Pancreatic Cancer: Is an Anti-VEGF Strategy Still Applicable?
Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA.
Invest New Drugs. 2008 Apr 1.[Epub]. University of California at San Francisco Comprehensive Cancer Center.
[Link to Abstract]


To all select abstracts from Pancreatica.org

 

 



About Us

Webmaster



DISCLAIMER: The information on this site is intended for educational purposes only;
all of the visitors to this site are strongly encouraged to read the Full Disclaimer.


Copyright © 1997-2008 ~ All Rights Reserved
Site last updated: June 28, 2008
The Pancreatic Duct
webmaster